BioMarin Pharma Q3 Net Loss Deepens, Revenue Rises

Shares of BioMarin Pharmaceutical (NASDAQ: BMRN  ) shares are down in post-market trading following the release of the company's Q3 results. For the quarter, revenue was just under $137 million, or nearly 7% higher than the $128 million it posted in the same period the previous year. Bottom line, however, plunged more deeply into the red, as the firm booked a net loss of $53.0 million ($0.38 per diluted share), against Q3 2012's shortfall of $5.4 million ($0.04).

On average, analysts had been expecting revenue of $140 million and a per-share loss of $0.30.

The company provided forward guidance for fiscal 2013. Total revenue for the year is anticipated to come in at $530 million to $555 million, with a net loss of $160 million to $185 million.http://investors.bmrn.com/releasedetail.cfm?ReleaseID=800324 

After the results were announced today, the company's stock dropped by 2.9%, or $1.99, to $66.97 in after-hours trading.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2699034, ~/Articles/ArticleHandler.aspx, 4/17/2014 5:43:59 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement